Welcome!
Welcome to the new CancerGRACE.org! Explore our fresh look and improved features—take a quick tour to see what’s new.
This long-overdue podcast by Dr. Mark Millard, Medical Director of the Baylor Martha Foster Lung Care Center and Professor of Pulmonology at Baylor University in Dallas, TX, focuses on many aspects of smoking cessation: how physicians can effectively discuss it with patients, how anyone can discuss the issue constructively with a smoker, and how someone motivated to quit can use a wide range of tools -- both behavioral and medical -- to optimize their chance of quitting for good.
Here are the audio and video versions of the podcast, along with the transcript and figures for the program.
Dr. Millard Tips and Tools for Smoking Cessation Audio Podcast
Dr. Millard Tips and Tools for Smoking Cessation Transcript
Dr. Millard Tips and Tools for Smoking Cessation Figures
This program was produced in partnership with the LUNGevity Foundation, and we thank them for their support.
Next up: The long-awaited "Highlights of Lung Cancer, 2011" podcasts from the presentation by Dr. Weiss several weeks ago.
Please feel free to offer comments and raise questions in our
discussion forums.
Bispecifics, or bispecific antibodies, are advanced immunotherapy drugs engineered to have two binding sites, allowing them to latch onto two different targets simultaneously, like a cancer cell and a T-cell, effectively...
The prefix “oligo–” means few. Oligometastatic (at diagnosis) Oligoprogression (during treatment)
There will be a discussion, “Studies in Oligometastatic NSCLC: Current Data and Definitions,” which will focus on what we...
Radiation therapy is primarily a localized treatment, meaning it precisely targets a specific tumor or area of the body, unlike systemic treatments (like chemotherapy) that affect the whole body.
The...
Biomarkers are genetic mutations (like EGFR, ALK, KRAS, BRAF) or protein levels (like PD-L1) in tumor cells that help guide personalized treatment, especially NSCLC, directing patients to targeted therapies or immunotherapies...
Hi Stan! So good to hear from you. I'm sorry for the late response. I too have been out of town with family and missed your post, probably because I was...
It is so good to hear from you! And I am so happy to hear that your holidays have been good and that you are doing well. It sounds like your...
Welcome to the new CancerGRACE.org! Explore our fresh look and improved features—take a quick tour to see what’s new.
An antibody–drug conjugate (ADC) works a bit like a Trojan horse. It has three main components: